 |
|
|
| |
Safety, Efficacy and Durability of Long-acting Cabotegravir (CAB) and Rilpivirine (RPV) as Two-Drug IM Maintenance Therapy for HIV-1 Infection: LATTE-2 Week 160 Results
|
| |
| |
Reported by Jules Levin
Glasgow Oct 27-31 2018
David A. Margolis,1Juan Gonzalez Garcia,2Hans-Jürgen Stellbrink,3Yazdan Yazdanpanah,4Gary Richmond,5Graham Smith,6Kenneth Sutton,1David Dorey,7Feifan Zhang,8Kimberly Smith,1Peter Williams,9William Spreen1
1ViiV Healthcare, Research Triangle Park, NC, USA; 2Hospital La Paz, Madrid, Spain; 3ICH Study Center, Hamburg, Germany; 4Hôpital Bichat Claude Bernard, Paris, France; 5Gary J. Richmond, MD, PA, Fort Lauderdale, FL, USA; 6Maple Leaf Research, Toronto, ON, Canada; 7GlaxoSmithKline, Mississauga, ON, Canada; 8GlaxoSmithKline, Collegeville, PA, USA; 9Janssen Research and Development, Beerse, Belgium
|
| |
|
|
|
|
|
